LISBURN PHARMA LIMITED
Summary
LISBURN PHARMA LIMITED was set up on Friday, August 10, 2018. Their current partial address is Carnbane House Shepherds Way and the company status is Active.
Credit Score
Latest Accounts Filed:
31/12/2025
Next Set of Accounts Due:
30/09/2027
Company Vitals
Company Name:
LISBURN PHARMA LIMITED
Time in Business:
8 years
Company Number:
NI654966
Current Status:
Active
Company Category:
Private Limited Company
Country of Origin:
United Kingdom
Principal Activity:
None Supplied
Registered Address:
Carnbane House Shepherds Way
Carnbane Industrial Estate
Newry
United Kingdom
BT35 6EE
Filing History
| Submission | Date | Type |
|---|---|---|
| Accounts with accounts type total exemption full | 2026-11-04 | AA |
| Confirmation statement with no updates | 2026-08-13 | CS01 |
| Change person director company with change date | 2026-03-04 | CH01 |
| Change person director company with change date | 2026-03-02 | CH01 |
| Appoint person secretary company with name date | 2026-01-29 | AP03 |
| Confirmation statement with updates | 2025-10-02 | CS01 |
| Accounts with accounts type total exemption full | 2025-07-16 | AA |
| Appoint person director company with name date | 2025-06-17 | AP01 |
| Termination director company with name termination date | 2024-11-01 | TM01 |
| Accounts with accounts type total exemption full | 2024-09-05 | AA |
| Confirmation statement with no updates | 2024-08-10 | CS01 |
| Appoint person director company with name date | 2024-08-10 | AP01 |
| Termination director company with name termination date | 2024-08-10 | TM01 |
| Appoint person director company with name date | 2024-02-09 | AP01 |
| Termination director company with name termination date | 2024-02-09 | TM01 |
| Accounts with accounts type total exemption full | 2023-10-16 | AA |
| Confirmation statement with no updates | 2023-08-11 | CS01 |
| Appoint person director company with name date | 2023-05-10 | AP01 |
| Termination director company with name termination date | 2023-05-10 | TM01 |
| Legacy | 2022-10-21 | AGREEMENT2 |